Skip to main content
Mijn bibliotheek
Shop
Nieuws Boeken Tijdschriften E-learning Web-tv Video Audio
Tips voor Mijn BSL
UITGEBREID ZOEKEN
Inloggen
Top
Gepubliceerd in:
Introduction hoofdstuk lezen eerste hoofdstuk lezen

2014 | OriginalPaper | Hoofdstuk

13. Founder mutations in the Netherlands: geographical distribution of the most prevalent mutations in the low-density lipoprotein receptor and apolipoprotein B genes*

Auteurs : D. M. Kusters, R. Huijgen, J. C. Defesche, M. N. Vissers, I. Kindt, B. A. Hutten, J. J. P. Kastelein

Gepubliceerd in: Founder mutations in inherited cardiac diseases in the Netherlands

Uitgeverij: Bohn Stafleu van Loghum

Log in om toegang te krijgen
share
DELEN

Deel dit onderdeel of sectie (kopieer de link)

  • Optie A:
    Klik op de rechtermuisknop op de link en selecteer de optie “linkadres kopiëren”
  • Optie B:
    Deel de link per e-mail
    Link delen
publish
Publiceer nu

Samenvatting

Background

In the Netherlands, a screening programme was set up in 1994 in order to identify all patients with familial hypercholesterolaemia (FH). After 15 years of screening, we evaluated the geographical distribution, possible founder effects and clinical phenotype of the 12 most prevalent FH gene mutations.

Methods

Patients who carried one of the 12 most prevalent mutations, index cases and those identified between 1994 and 2009 through the screening programme and whose postal code was known were included in the study. Low-density lipoprotein cholesterol (LDL-C) levels at the time of screening were retrieved. The prevalence of identified FH patients in each postal code area was calculated and visualised in different maps.

Results

A total of 10,889 patients were included in the study. Mean untreated LDL-C levels ranged from 4.4 to 6.4 mmol/l. For almost all mutations, a region of high prevalence could be observed. In total, 51 homozygous patients were identified in the Netherlands, of which 13 true homozygous for one of the 12 most prevalent mutations. The majority of them were living in high-prevalence areas for that specific mutation.

Conclusions

Phenotypes with regard to LDL-C levels varied between the 12 most prevalent FH mutations. For most of these mutations, a founder effect was observed. Our observations can have implications with regard to the efficiency of molecular screening and physician’s perception of FH and to the understanding of the prevalence and distribution of homozygous patients in the Netherlands.
vorige hoofdstuk Recurrent and founder mutations in the Netherlands: Extensive clinical variability in Marfan syndrome patients with a single novel recurrent fibrillin-1 missense mutation*
Literatuur
1.
Goldstein JL, Hobbs HH, Brown MS. The metabolic and molecular bases of inherited disease. New York: McGraw-Hill; 2001.
2.
Lansberg PJ, Tuzgol S, van de Ree MA, et al. Higher prevalence of familial hypercholesterolemia than expected in adult patients of four family practices in Netherlands. Ned Tijdschr Geneeskd. 2000;144:1437–40.PubMed
3.
Fouchier SW, Defesche JC, Umans-Eckenhausen MW, et al. The molecular basis of familial hypercholesterolemia in the Netherlands. Hum Genet. 2001;109:602–15.CrossRefPubMed
4.
Innerarity TL, Mahley RW, Weisgraber KH, et al. Familial defective apolipoprotein B-100: a mutation of apolipoprotein B that causes hypercholesterolemia. J Lipid Res. 1990;31:1337–49.PubMed
5.
Leigh SE, Foster AH, Whittall RA, et al. Update and analysis of the University College London low density lipoprotein receptor familial hypercholesterolemia database. Ann Hum Genet. 2008;72:485–98.CrossRefPubMed
6.
Huijgen R, Kindt I, Fouchier SW, et al. Functionality of sequence variants in the genes coding for the low-density lipoprotein receptor and apolipoprotein B in individuals with inherited hypercholesterolemia. Hum Mutat. 2010;31:752–60.CrossRefPubMed
7.
Junyent M, Gilabert R, Jarauta E, et al. Impact of low-density lipoprotein receptor mutational class on carotid atherosclerosis in patients with familial hypercholesterolemia. Atherosclerosis. 2010;208:437–41.CrossRefPubMed
8.
Umans-Eckenhausen MA, Sijbrands EJ, Kastelein JJ, et al. Low-density lipoprotein receptor gene mutations and cardiovascular risk in a large genetic cascade screening population. Circulation. 2002;106:3031–6.CrossRefPubMed
9.
Wonderling D, Umans-Eckenhausen MA, Marks D, et al. Cost-effectiveness analysis of the genetic screening programme for familial hypercholesterolemia in the Netherlands. Semin Vasc Med. 2004;4:97–104.CrossRefPubMed
10.
Defesche JC. Familial hypercholesterolaemia. In: Betteridge DJ, editor. Lipids and vascular disease. London: Martin Dunitz; 2000. p. 65–76.
11.
Huijgen R, Vissers MN, Defesche JC, et al. Familial hypercholesterolemia: current treatment and advances in management. Expert Rev Cardiovasc Ther. 2008;6:567–81.CrossRefPubMed
12.
Cobbaert C, Boerma GJ, Lindemans J. Evaluation of the Cholestech L.D.X. desktop analyser for cholesterol, HDL-cholesterol, and triacylglycerols in heparinized venous blood. Eur J Clin Chem Clin Biochem. 1994;32:391–4.PubMed
13.
Hofman N, Postema PG, van Langen IM, et al. Genetic identification of patients and families with a long-QT syndrome: large regional differences in the result of 10 years. Ned Tijdschr Geneeskd. 2007;151:644–8.PubMed
14.
StOEH. Annual report 2008. Amsterdam: StOEH; 2009.
15.
Huijgen R, Kindt I, Verhoeven SB, et al. Two years after molecular diagnosis of familial hypercholesterolemia: majority on cholesterol-lowering treatment but a minority reaches treatment goal. PLoS ONE. 2010;5:e9220.CrossRefPubMedPubMedCentral
16.
Umans-Eckenhausen MA, Sijbrands EJ, Kastelein JJ, et al. Low-density lipoprotein receptor gene mutations and cardiovascular risk in a large genetic cascade screening population. Circulation. 2002;106:3031–6.CrossRefPubMed
17.
Fouchier SW, Kastelein JJ, Defesche JC. Update of the molecular basis of familial hypercholesterolemia in the Netherlands. Hum Mutat. 2005;26:550–6.CrossRefPubMed
18.
Kotze MJ, Langenhoven E, Warnich L, et al. The molecular basis and diagnosis of familial hypercholesterolaemia in South African Afrikaners. Ann Hum Genet. 1991;55:115–21.CrossRefPubMed
19.
Defesche JC, Van Diermen DE, Lansberg PJ, et al. South African founder mutations in the low-density lipoprotein receptor gene causing familial hypercholesterolemia in the Dutch population. Hum Genet. 1993;92:567–70.CrossRefPubMed
20.
Defesche JC, Van Diermen DE, Hayden MR, et al. Origin and migration of an Afrikaner founder mutation FHAfrikaner-2 (V408M) causing familial hypercholesterolemia. Gene Geogr. 1996;10:1–10.PubMed
21.
Austin MA, Hutter CM, Zimmern RL, et al. Genetic causes of monogenic heterozygous familial hypercholesterolemia: a HuGE prevalence review. Am J Epidemiol. 2004;160:407–20.CrossRefPubMed
22.
Myant NB, Forbes SA, Day IN, et al. Estimation of the age of the ancestral arginine3500–>glutamine mutation in human apoB-100. Genomics. 1997;45:78–87.CrossRefPubMed
23.
Yu W, Nohara A, Higashikata T, et al. Molecular genetic analysis of familial hypercholesterolemia: spectrum and regional difference of LDL receptor gene mutations in Japanese population. Atherosclerosis. 2002;165:335–42.CrossRefPubMed
24.
Khoo KL, van Acker P, Defesche JC, et al. Low-density lipoprotein receptor gene mutations in a Southeast Asian population with familial hypercholesterolemia. Clin Genet. 2000;58:98–105.CrossRefPubMed
25.
Vuorio AF, Turtola H, Piilahti KM, et al. Familial hypercholesterolemia in the Finnish north Karelia. A molecular, clinical, and genealogical study. Arterioscler Thromb Vasc Biol. 1997;17:3127–38.CrossRefPubMed
26.
Betard C, Kessling AM, Roy M, et al. Molecular genetic evidence for a founder effect in familial hypercholesterolemia among French Canadians. Hum Genet. 1992;88:529–36.CrossRefPubMed
27.
Steyn K, Goldberg YP, Kotze MJ, et al. Estimation of the prevalence of familial hypercholesterolaemia in a rural Afrikaner community by direct screening for three Afrikaner founder low density lipoprotein receptor gene mutations. Hum Genet. 1996;98:479–84.CrossRefPubMed
28.
den Dunnen JT, Antonarakis SE. Mutation nomenclature extensions and suggestions to describe complex mutations: a discussion. Hum Mutat. 2000;15:7–12.CrossRef
Metagegevens
Titel
Founder mutations in the Netherlands: geographical distribution of the most prevalent mutations in the low-density lipoprotein receptor and apolipoprotein B genes*
Auteurs
D. M. Kusters
R. Huijgen
J. C. Defesche
M. N. Vissers
I. Kindt
B. A. Hutten
J. J. P. Kastelein
Copyright
2014
Uitgeverij
Bohn Stafleu van Loghum
Boek
Founder mutations in inherited cardiac diseases in the Netherlands

Print ISBN: 978-90-368-0704-3

Elektronisch ISBN: 978-90-368-0705-0

Copyright: 2014

DOI
https://doi.org/10.1007/978-90-368-0705-0_13